Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erica L Wegrzyn

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Journal of Pain Research|October 29, 2020
The United States Drug Enforcement Administration and Prescription Opioid Production Quotas: An End Game of Eradication?Michael E Schatman, Erica L Wegrzyn
Journal of Pain Research|September 24, 2016
OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage formJeffrey Fudin, Mena Raouf, Erica L Wegrzyn
JAMA Oncology|April 15, 2021
Questionable Conceptualizations of Nonmedical Use Can Contribute to Needless DistressMichael E Schatman, Hannah Shapiro, Erica L Wegrzyn
Journal of Pain Research|January 4, 2018
Safety concerns with the Centers for Disease Control opioid calculatorJeffrey Fudin, Mena Raouf, Erica L Wegrzyn, et al.
Journal of Pain Research|January 11, 2018
Pharmacogenetic guidance: individualized medicine promotes enhanced pain outcomesLisa Lynn Dragic, Erica L Wegrzyn, Michael E Schatman, et al.
Journal of Pain Research|December 21, 2016
Pharmacotherapeutic considerations for chronic pain in chronic kidney and end-stage renal diseaseRoy O Mathew, Jeffrey J Bettinger, Erica L Wegrzyn, et al.
Journal of Pain Research|September 9, 2020
FentaloguesAmelia L Persico, Erica L Wegrzyn, Jeffrey Fudin, et al.
Clinical Pharmacology and Therapeutics|April 3, 2018
The CDC Opioid Guideline: Proponent Interpretation Has Led to MisinformationErica L Wegrzyn, Ausim M Chaghtai, Charles E Argoff, et al.
Neurologic Clinics|July 17, 2025
Exploring Beyond Mu: Nonopioid AnalgesicsBrittany A Henault, Katrina M Dean, Jeffrey J Bettinger, et al.
Journal of Pain Research|July 2, 2020
A Randomized, Crossover, Pharmacokinetic and Adhesion Performance Study of a Lidocaine Topical System 1.8% During Physical Activity and Heat Treatment in Healthy SubjectsJeffrey Fudin, Erica L Wegrzyn, Emileigh Greuber, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of Pain Research|October 29, 2020
The United States Drug Enforcement Administration and Prescription Opioid Production Quotas: An End Game of Eradication?Michael E Schatman, Erica L Wegrzyn
Journal of Pain Research|September 24, 2016
OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage formJeffrey Fudin, Mena Raouf, Erica L Wegrzyn
JAMA Oncology|April 15, 2021
Questionable Conceptualizations of Nonmedical Use Can Contribute to Needless DistressMichael E Schatman, Hannah Shapiro, Erica L Wegrzyn
Journal of Pain Research|January 4, 2018
Safety concerns with the Centers for Disease Control opioid calculatorJeffrey Fudin, Mena Raouf, Erica L Wegrzyn, et al.
Journal of Pain Research|January 11, 2018
Pharmacogenetic guidance: individualized medicine promotes enhanced pain outcomesLisa Lynn Dragic, Erica L Wegrzyn, Michael E Schatman, et al.
Journal of Pain Research|December 21, 2016
Pharmacotherapeutic considerations for chronic pain in chronic kidney and end-stage renal diseaseRoy O Mathew, Jeffrey J Bettinger, Erica L Wegrzyn, et al.
Journal of Pain Research|September 9, 2020
FentaloguesAmelia L Persico, Erica L Wegrzyn, Jeffrey Fudin, et al.
Clinical Pharmacology and Therapeutics|April 3, 2018
The CDC Opioid Guideline: Proponent Interpretation Has Led to MisinformationErica L Wegrzyn, Ausim M Chaghtai, Charles E Argoff, et al.
Neurologic Clinics|July 17, 2025
Exploring Beyond Mu: Nonopioid AnalgesicsBrittany A Henault, Katrina M Dean, Jeffrey J Bettinger, et al.
Journal of Pain Research|July 2, 2020
A Randomized, Crossover, Pharmacokinetic and Adhesion Performance Study of a Lidocaine Topical System 1.8% During Physical Activity and Heat Treatment in Healthy SubjectsJeffrey Fudin, Erica L Wegrzyn, Emileigh Greuber, et al.
Pageof 2